Abstract:Background: Neuronal abnormalities are closely associated with major depressive disorder (MDD). Available evidence suggests a role for microRNAs (miRNAs) in regulating the expression of genes involved in MDD. Hence, miRNAs that can be potential therapeutic targets need to be identified. Methods: A mouse model of chronic unpredictable stress (CUS) was used to evaluate the function of miRNAs in MDD. miR-144-5p was screened from the hippocampi of CUS mice based on sequencing results. Adenovirus-associated vectors were used to overexpress or knockdown miR-144-5p in mice. BpV(pic) and LY294002 were used to determine the relationship between miR-144-5p target genes PTEN and TLR4 in neuronal impairment caused by miR-144-5p deficiency. Western blotting, immunofluorescence, ELISA immunosorbent assay, and Golgi staining were used to detect neuronal abnormalities. Serum samples from healthy individuals and patients with MDD were used to detect miR-144-5p levels in the serum and serum exosomes using qRT-PCR. Results: miR-144-5p expression was significantly decreased within the hippocampal dentate gyrus (DG) of CUS mice. Upregulation of miR-144-5p in the DG ameliorated depression-like behavior in CUS mice and attenuated neuronal abnormalities by directly targeting PTEN and TLR4 expression. Furthermore, miR-144-5p knockdown in normal mice led to depression-like behavior via inducing neuronal abnormalities, including abnormal neurogenesis, neuronal apoptosis, altered synaptic plasticity, and neuroinflammation. miR-144-5p deficiency-mediated neuronal impairment was mediated by PI3K/Akt/FoxO1 signaling. Furthermore, miR-144-5p levels were downregulated in the sera of patients with MDD and associated with depressive symptoms. Consistently, serum exosome-derived miR-144-5p levels were decreased in patients with MDD. Conclusion: miR-144-5p plays a vital role in regulating neuronal abnormalities in depression. Our findings provide translational evidence that miR-144-5p is a new potential therapeutic target for MDD.

Changes in Mirna-132 and Mir-124 Levels in Non-Treated and Citalopram-Treated Patients with Depression

Blood Mir-144-3p: a Novel Diagnostic and Therapeutic Tool for Depression

Increased Mir-132 Level is Associated with Visual Memory Dysfunction in Patients with Depression

Effects of Neuronavigation-Guided Rtms on Serum BDNF, TrkB and VGF Levels in Depressive Patients with Suicidal Ideation

Alterations of Microrna-124 Expression in Peripheral Blood Mononuclear Cells in Pre- and Post-Treatment Patients with Major Depressive Disorder.

Expression changes of microRNA-132 in the peripheral blood mononuclear cells in patients with major depressive disorder before and after treatment

Abnormal Expression Profile of Plasma-Derived Exosomal Micrornas in Patients with Treatment-Resistant Depression

MicroRNA132 associated multimodal neuroimaging patterns in unmedicated major depressive disorder.

Increased Expression of a Novel Mirna in Peripheral Blood is Negatively Correlated with Hippocampal Volume in Patients with Major Depressive Disorder.

The Changes In, and Relationship Between, Plasma Nitric Oxide and Corticotropin‐releasing Hormone in Patients with Major Depressive Disorder

Mir-16 and Fluoxetine Both Reverse Autophagic and Apoptotic Change in Chronic Unpredictable Mild Stress Model Rats.

MicroRNA-124 influenced depressive symptoms via large-scale brain connectivity in major depressive disorder patients

Knockdown of Mir-124 Reduces Depression-like Behavior by Targeting CREB1 and BDNF.

Clinical and preclinical evaluation of miR-144-5p as a key target for major depressive disorder

Exosomal miR-1202 mediates Brodmann Area 44 functional connectivity changes in medication-free patients with major depressive disorder: An fMRI study

The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder

Genome-Wide miRNA Expression Alterations in Nucleus Accumbens Provide Insights into Chronic Stress and Treatment in Depression

Elevated Plasma Levels of Mature Brain-Derived Neurotrophic Factor in Major Depressive Disorder Patients with Higher Suicidal Ideation

Mir-124 Exacerbates Depressive-Like Behavior by Targeting Ezh2 to Induce Autophagy

Plasma Brain-Derived Neurotrophic Factor (BDNF) Concentration and the BDNF Val66Met Polymorphism in Suicide: a Prospective Study in Patients with Depressive Disorder

The Relationship between Level of BDNF in Serum and Depressive Symptoms and Cognitive Dysfunction of Patients with Major Depression